Novo Nordisk A/S (NYSE:NVO) was upgraded by analysts at Bank of America from a “neutral” rating to a “buy” rating in a report issued on Wednesday, MarketBeat Ratings reports.

NVO has been the subject of several other reports. Zacks Investment Research lowered Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Monday, October 9th. BNP Paribas lowered Novo Nordisk A/S from an “outperform” rating to a “neutral” rating in a research report on Monday, September 25th. Morgan Stanley raised Novo Nordisk A/S from an “equal weight” rating to an “overweight” rating in a research report on Friday, December 1st. Finally, BidaskClub raised Novo Nordisk A/S from a “sell” rating to a “hold” rating in a research report on Saturday, August 12th. Three investment analysts have rated the stock with a sell rating, four have issued a hold rating and three have given a buy rating to the company. The stock presently has an average rating of “Hold” and an average target price of $55.00.

Novo Nordisk A/S (NVO) traded up $1.37 during midday trading on Wednesday, reaching $52.07. The company had a trading volume of 2,149,087 shares, compared to its average volume of 2,098,419. The stock has a market cap of $130,152.00, a price-to-earnings ratio of 22.29, a P/E/G ratio of 3.05 and a beta of 0.63. Novo Nordisk A/S has a twelve month low of $32.83 and a twelve month high of $52.45.

In other Novo Nordisk A/S news, insider Eric S. Sprott bought 50,000 shares of the firm’s stock in a transaction dated Wednesday, November 8th. The stock was purchased at an average cost of $8.34 per share, with a total value of $417,000.00.

Institutional investors have recently made changes to their positions in the company. Proficio Capital Partners LLC grew its stake in shares of Novo Nordisk A/S by 6.1% during the 2nd quarter. Proficio Capital Partners LLC now owns 2,622 shares of the company’s stock worth $111,000 after acquiring an additional 150 shares during the period. AlphaMark Advisors LLC grew its stake in shares of Novo Nordisk A/S by 1.1% during the 2nd quarter. AlphaMark Advisors LLC now owns 2,645 shares of the company’s stock worth $113,000 after acquiring an additional 30 shares during the period. MUFG Americas Holdings Corp grew its stake in shares of Novo Nordisk A/S by 100.0% during the 2nd quarter. MUFG Americas Holdings Corp now owns 3,000 shares of the company’s stock worth $129,000 after acquiring an additional 1,500 shares during the period. Zions Bancorporation grew its stake in shares of Novo Nordisk A/S by 677.1% during the 3rd quarter. Zions Bancorporation now owns 2,852 shares of the company’s stock worth $137,000 after acquiring an additional 2,485 shares during the period. Finally, Parallel Advisors LLC grew its stake in shares of Novo Nordisk A/S by 44.4% during the 2nd quarter. Parallel Advisors LLC now owns 4,108 shares of the company’s stock worth $174,000 after acquiring an additional 1,264 shares during the period. 6.18% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: This story was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this story on another website, it was illegally copied and reposted in violation of US and international copyright and trademark laws. The original version of this story can be read at https://www.americanbankingnews.com/2017/12/06/novo-nordisk-as-nvo-lifted-to-buy-at-bank-of-america.html.

About Novo Nordisk A/S

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company’s diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs.

Analyst Recommendations for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.